Why the study?
Do novel interventional therapies (baroreflex activation therapy, carotid stenting, arteriovenous shunts) reduce blood pressure in patients with treatment-resistant hypertension?
Do novel interventional therapies (baroreflex activation therapy, carotid stenting, arteriovenous shunts) reduce blood pressure in patients with treatment-resistant hypertension?
Device-based interventional therapies offer promising alternative options for blood pressure control in treatment-resistant hypertension, but require further validation of long-term safety and clinical outcomes.
Answers are grounded in this paper and cite their sources.
Device therapies should not yet change practice in resistant hypertension; leaves open need for long-term outcome trials.
Pharmacologic therapy for hypertension is effective for the majority of patients with hypertension, but there is a subset of the population with treatment-resistant hypertension who cannot achieve their blood pressure goal despite taking multiple medications. Since these patients are at increased risk of cardiovascular disease and end-organ damage, additional therapies must be considered. This review discusses several novel interventional therapies-including baroreflex activation therapy, baroreceptor stenting, and creation of an arteriovenous shunt-that may provide alternative options for blood pressure control in those with treatment-resistant hypertension. All of these therapies remain investigational, and each has its own strengths and weaknesses that will be critical to assess as they come to market.
No takes yet. Share an insight, caveat, or question.
Paivanas et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: